Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Washington man pleads guilty to groping woman on San Diego to Seattle flightTennessee GOP Rep. Andy Ogles draws Republican and Democratic challengersByron leads Hendrick Motorsports to 1What to expect in Michigan's state house special electionsHeim homers with 4 RBIs as Rangers win 12He once swore off politics. Now, this Georgia activist is trying to recruit people who seldom voteFormer owner of gas station chain gets Trump's endorsement in Wisconsin congressional racePaurova becomes eighth Oregon State player to enter the portalDonovan Mitchell scores 33 points, Cavaliers clinch playoff spot with 129Government increases support for Ukraine, extends NZDF deployment
2.7925s , 6498.8828125 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Global Gist news portal